News | CT Angiography (CTA) | November 29, 2016

Alcohol Consumption Shows No Effect on Coronary Arteries

Study of 1,925 patients using coronary CT angiography finds light to moderate consumption does not increase incidence of coronary artery disease

coronary CT angiography, CCTA, alcohol consumption, CAD, coronary artery disease, RSNA 2016

November 29, 2016 — Researchers using coronary computed tomography angiography (CCTA) found no association between light to moderate alcohol consumption and coronary artery disease (CAD), according to a study presented at the 2016 annual meeting of the Radiological Society of North America (RSNA).

Some previous studies have suggested that light alcohol consumption may actually reduce the risk for CAD. However, data regarding regular alcohol consumption and its association with the presence of CAD remains controversial. For the new study, researchers looked at alcohol consumption, type of alcohol consumed, and presence of coronary plaques using CCTA.

"CCTA is an excellent diagnostic modality to noninvasively depict the coronary wall and identify atherosclerotic lesions," said study author Júlia Karády, M.D., from the MTA-SE Cardiovascular Imaging Research Group, Heart and Vascular Center at Semmelweis University in Budapest, Hungary. "Furthermore, we're able to characterize plaques and differentiate between several types. Prior studies used cardiovascular risk factors — like high cholesterol levels — and cardiovascular outcomes to study the effects of alcohol, but our study is unique in that we analyzed both drinkers and non-drinkers using CCTA, which may shed some light on how alcohol may or may not contribute to the development of fatty plaques in the arteries of the heart."

The researchers studied 1,925 consecutive patients referred for CCTA with suspected CAD. Information on alcohol consumption habits was collected using questionnaires about the amount and type of alcohol consumed. Using an in-house reporting platform that contained the patients' clinical and CCTA data, researchers were able to assess the relationship between atherosclerosis, clinical risk factors and patient drinking habits.

"About 40 percent of our patients reported regular alcohol consumption, with a median of 6.7 alcohol units consumed weekly," Karády said.

One unit translates to approximately 2 deciliters (dl) or 6.8 fluid ounces of beer, 1 dl or 3.4 ounces of wine, or 4 centiliters (cl) or 1.35 ounces of hard liquor.

The results showed that the amount of weekly alcohol consumption, whether light or moderate, was not associated with the presence of CAD. In addition, when researchers looked at different types of alcohol and the presence of coronary atherosclerosis, no associations were found.

"When we compared consumption between patients who had coronary artery plaques and those who had none, no difference was detected," Karády said. "Evaluating the relationship between light alcohol intake (maximum of 14 units per week) and presence of CAD, we again found no association. Furthermore, we analyzed the effect of different types of alcohol (beer, wine and hard liquor) on the presence of CAD, but no relationship was found."

Karády added that while no protective effect was detected among light drinkers, as previously thought, no harmful effects were detected either.

The researchers are in the process of expanding the study to include more patients and perform further analyses.

Independently of whether alcohol has any effect on the coronary arteries, moderate alcohol consumption has been associated with a number of potential side effects, including negative long-term effects on the brain and heart.

Co-authors on this study were Balint Szilveszter, M.D., Zsofia D. Drobni, M.D., Marton Kolossvary, M.D., Andrea Bartykowszki, M.D., Mihaly Karolyi, M.D., Ph.D., Adam Jermendy, M.D., Alexisz Panajotu, M.D., Zsolt Bagyura, M.D., and Pal Maurovich-Horvat, M.D., Ph.D., M.P.H.

For more information: www.rsna.org

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Videos | Cardiovascular Ultrasound| October 12, 2017
Sharon Mulvagh, M.D., FRCPC, FACC, FAHA, FASE, professor, Division of Cardiology, Department of Medicine, Dalhouse Un
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
SunTech Medical Receives Third-Party Validation of CT40 BP Spot-Check Device
News | Blood Pressure Monitor| October 11, 2017
October 11, 2017 — The CT40 spot-check device from SunTech Medical has received third-party validation for...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Medis Releases QAngio CT v3.1
Technology | Computed Tomography (CT)| October 09, 2017
Medis has released a new version of its QAngio CT (computed tomography), which can now be launched from the Medis Suite...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Overlay Init